Raludotatug deruxtecan (R-DXd), a CDH6-targeted ADC with the topoisomerase 1 inhibitor DXd, is currently in clinical trials for ovarian, renal and endometrial cancers, and exhibits promising clinical activity in ovarian cancer patients [16]. Here, CDH6 is linked to ovarian carcinoma.